|Articles|December 3, 2017
Opioid Use Disorder Drug Approval Highlights AJPB Week in Review
Author(s)AJPB staff
Top articles of the week from The American Journal of Pharmacy Benefits.
Advertisement
5. Study: Connected Pharmacy, Medical Benefits Improves Patient Proactivity in Healthcare
Integrated pharmacy and medical benefits may increase patient engagement in health coaching.
4. Diabetes Cure in Reach with Low-Calorie Diet
Reducing calorie intake may reverse type 2 diabetes.
3. Majority of Uninsured Patients Experienced Catastrophic Costs for Heart Attack Pre-ACA
Eighty-five percent of patients treated for heart attacks exceeded catastrophic costs before the passage of the Affordable Care Act.
2. FDA Warning: Vitamin B May Lead to Incorrect Lab Tests
Biotin interference in lab tests has resulted in at least 1 patient death.
1. Novel Opioid Use Disorder Drug Gains FDA Approval
The FDA approves the first monthly injectable buprenorphine for opioid use disoder.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Need to Know About Retatrutide's TRIUMPH-1 Phase 3 Results
2
Darovasertib Plus Crizotinib Shows Striking Efficacy in HLA-A2–Negative Metastatic Uveal Melanoma, OptimUM-02 Results Show
3
First-in-Human In Vivo CAR-T Therapy Shows Encouraging Activity in Relapsed/Refractory Multiple Myeloma
4
FDA Approves Ensitrelvir for Post-Exposure Prophylaxis of COVID-19 in Adolescents and Adults
5